106 related articles for article (PubMed ID: 32978057)
1. The curious phenomenon of early cardiac allograft rejection with hepatitis C‒infected donor heart transplants.
Woolley AE; Singh SK
J Heart Lung Transplant; 2020 Nov; 39(11):1208-1209. PubMed ID: 32978057
[No Abstract] [Full Text] [Related]
2. Cardiac allograft vasculopathy and secondary outcomes of hepatitis C-positive donor hearts at 1 year after transplantation.
Madan S; Patel SR; Jorde UP
J Heart Lung Transplant; 2020 Nov; 39(11):1318-1321. PubMed ID: 32680608
[No Abstract] [Full Text] [Related]
3. A Reason to be Positive: Early Cardiac Allograft Vasculopathy and Acute Rejection in Recipients of HCV+ Donor Hearts.
Dichiacchio L; Higgins AR
J Card Fail; 2024 May; 30(5):701-702. PubMed ID: 38218346
[No Abstract] [Full Text] [Related]
4. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
[TBL] [Abstract][Full Text] [Related]
5. The effect of donor gender on graft survival.
Zeier M; Döhler B; Opelz G; Ritz E
J Am Soc Nephrol; 2002 Oct; 13(10):2570-6. PubMed ID: 12239247
[TBL] [Abstract][Full Text] [Related]
6. Tobacco smoke exposure in either the donor or recipient before transplantation accelerates cardiac allograft rejection, vascular inflammation, and graft loss.
Khanna AK; Xu J; Uber PA; Burke AP; Baquet C; Mehra MR
Circulation; 2009 Nov; 120(18):1814-21. PubMed ID: 19841304
[TBL] [Abstract][Full Text] [Related]
7. Donor tissue-specific exosome profiling enables noninvasive monitoring of acute rejection in mouse allogeneic heart transplantation.
Habertheuer A; Korutla L; Rostami S; Reddy S; Lal P; Naji A; Vallabhajosyula P
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2479-2489. PubMed ID: 29499866
[TBL] [Abstract][Full Text] [Related]
8. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
Rayhill SC; Wu YM; Katz DA; Voigt MD; Labrecque DR; Kirby PA; Mitros FA; Kalil RS; Miller RA; Stolpen AH; Schmidt WN
Transplantation; 2007 Aug; 84(3):331-9. PubMed ID: 17700157
[TBL] [Abstract][Full Text] [Related]
9. Tanshinol suppresses cardiac allograft rejection in a murine model.
Lu C; Zeng YQ; Liu H; Xie Q; Xu S; Tu K; Dou C; Dai Z
J Heart Lung Transplant; 2017 Feb; 36(2):227-236. PubMed ID: 27574736
[TBL] [Abstract][Full Text] [Related]
10. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy.
Yang J; Popoola J; Khandwala S; Vadivel N; Vanguri V; Yuan X; Dada S; Guleria I; Tian C; Ansari MJ; Shin T; Yagita H; Azuma M; Sayegh MH; Chandraker A
Circulation; 2008 Feb; 117(5):660-9. PubMed ID: 18212277
[TBL] [Abstract][Full Text] [Related]
11. Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the International Society for Heart and Lung Transplantation Registry.
Khush KK; Kubo JT; Desai M
J Heart Lung Transplant; 2012 May; 31(5):459-66. PubMed ID: 22418079
[TBL] [Abstract][Full Text] [Related]
12. The multidimensional perspective of cardiac allograft rejection.
Deng M; Cadeiras M; Reed EF
Curr Opin Organ Transplant; 2013 Oct; 18(5):569-72. PubMed ID: 23995374
[No Abstract] [Full Text] [Related]
13. Induction of donor-specific tolerance to cardiac but not skin or renal allografts by intrathymic injection of splenocyte alloantigen.
Nakafusa Y; Goss JA; Mohanakumar T; Flye MW
Transplantation; 1993 Apr; 55(4):877-82. PubMed ID: 8475563
[TBL] [Abstract][Full Text] [Related]
14. Impact of Traumatically Brain-Injured Donors on Outcomes After Heart Transplantation.
Suarez-Pierre A; Crawford TC; Zhou X; Lui C; Fraser CD; Etchill E; Sharma K; Higgins RS; Whitman GJ; Kilic A; Choi CW
J Surg Res; 2019 Aug; 240():40-47. PubMed ID: 30909064
[TBL] [Abstract][Full Text] [Related]
15. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients.
Sayegh MH; Zheng XG; Magee C; Hancock WW; Turka LA
Transplantation; 1997 Dec; 64(12):1646-50. PubMed ID: 9422396
[TBL] [Abstract][Full Text] [Related]
16. The combined organ effect: protection against rejection?
Rana A; Robles S; Russo MJ; Halazun KJ; Woodland DC; Witkowski P; Ratner LE; Hardy MA
Ann Surg; 2008 Nov; 248(5):871-9. PubMed ID: 18948817
[TBL] [Abstract][Full Text] [Related]
17. Donor Simvastatin Treatment in Heart Transplantation.
Nykänen AI; Holmström EJ; Tuuminen R; Krebs R; Dhaygude K; Kankainen M; Jokinen JJ; Lommi J; Helanterä I; Räisänen-Sokolowski A; Syrjälä SO; Lemström KB
Circulation; 2019 Aug; 140(8):627-640. PubMed ID: 31352795
[TBL] [Abstract][Full Text] [Related]
18. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Woolley AE; Singh SK; Goldberg HJ; Mallidi HR; Givertz MM; Mehra MR; Coppolino A; Kusztos AE; Johnson ME; Chen K; Haddad EA; Fanikos J; Harrington DP; Camp PC; Baden LR;
N Engl J Med; 2019 Apr; 380(17):1606-1617. PubMed ID: 30946553
[TBL] [Abstract][Full Text] [Related]
19. Divergent role of donor dendritic cells in rejection versus tolerance of allografts.
Ueno T; Tanaka K; Jurewicz M; Murayama T; Guleria I; Fiorina P; Paez JC; Augello A; Vergani A; Wong M; Smith RN; Abdi R
J Am Soc Nephrol; 2009 Mar; 20(3):535-44. PubMed ID: 19129312
[TBL] [Abstract][Full Text] [Related]
20. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts.
Khapra AP; Agarwal K; Fiel MI; Kontorinis N; Hossain S; Emre S; Schiano TD
Liver Transpl; 2006 Oct; 12(10):1496-503. PubMed ID: 16964597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
